SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2596)12/3/2018 1:40:14 PM
From: Miljenko Zuanic  Respond to of 3559
 
<Finally, REGN1979 is being investigated in combination with Libtayo® (cemiplimab-rwlc) in an ongoing Phase 1 study, which we believe is the first to combine a CD20xCD3 bispecific antibody with a PD-1 or PD-L1 inhibitor." >


Luck off any specific wording on this combo leave me with impression that combo is "eventually dead"! Tox would be interesting point????



To: Miljenko Zuanic who wrote (2596)12/3/2018 10:56:44 PM
From: Felix B  Read Replies (1) | Respond to of 3559
 
How does REGN compare H2H and I thought it was a somewhat small pt population so will be slow to recruit?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News